1985
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimen
1981
Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma. Blood 1981, 58: 45-51. DOI: 10.1182/blood.v58.1.45.45.Peer-Reviewed Original ResearchLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesPredicting Long-Term SurvivalExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisFactors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trials
1979
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine